Original Research

Published on 10 Apr 2023

Long-term effects of lumacaftor/ivacaftor on paranasal sinus abnormalities in children with cystic fibrosis detected with magnetic resonance imaging

in Respiratory Pharmacology

Lena Wucherpfennig
Felix Wuennemann
Monika Eichinger
Angelika Seitz
Ingo Baumann
Mirjam Stahl
Simon Y. Graeber
Shengkai Zhao
Jaehi Chung
Jens-Peter Schenk

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1161891

2,056 views
7 citations

Original Research

Published on 04 Apr 2023

Low-dose of caffeine alleviates high altitude pulmonary edema via regulating mitochondrial quality control process in AT1 cells

in Respiratory Pharmacology

Liuyang Tian
Zhilong Jia
Yan Yan
Qian Jia
Wenjie Shi
Saijia Cui
Huining Chen
Yang Han
Xiaojing Zhao
Kunlun He

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1155414

4,187 views
1 citation

Review

Published on 30 Mar 2023

Sex chromosome complement and sex steroid signaling underlie sex differences in immunity to respiratory virus infection

in Respiratory Pharmacology

Reegan A. J. Miller
Abigael P. Williams
Susan Kovats

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1150282

4,020 views
4 citations

Original Research

Published on 29 Mar 2023

Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

in Respiratory Pharmacology

Daniel Morales-Cano
Jose Luis Izquierdo-García
Bianca Barreira
Sergio Esquivel-Ruiz
Maria Callejo
Rachele Pandolfi
Palmira Villa-Valverde
Ignacio Rodríguez
Angel Cogolludo
Jesus Ruiz-Cabello

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1021535

3,375 views
3 citations

Review

Published on 21 Mar 2023

Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor

in Respiratory Pharmacology

Burkhard Tümmler

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1158207

7,247 views
12 citations

Clinical Trial

Published on 21 Mar 2023

Comparison of treatment persistence, adherence, and risk of exacerbation in patients with COPD treated with single-inhaler versus multiple-inhaler triple therapy: A prospective observational study in China

in Respiratory Pharmacology

Ling Lin
Cong Liu
Wei Cheng
Qing Song
Yuqin Zeng
Xin Li
Dingding Deng
Dan Liu
Yan Chen
Shan Cai

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1147985

3,394 views
4 citations

Review

Published on 16 Mar 2023

Functional enhancement strategies to potentiate the therapeutic properties of mesenchymal stromal cells for respiratory diseases

in Respiratory Pharmacology

Miquéias Lopes-Pacheco
Patricia R. M. Rocco

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1067422

8,178 views
10 citations

Original Research

Published on 16 Mar 2023

Better response to Tanreqing injection in frequent acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients—Real-world evidence from a nationwide registry (ACURE) study

in Respiratory Pharmacology

Guohui Fan
Dingyi Wang
Sinan Wu
Demin Li
Xiaoxia Ren
Fen Dong
Kewu Huang
Yahong Chen
Hongchun Zhang
Chen Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1118143

2,280 views
2 citations

Review

Published on 16 Mar 2023

The protective effects of baicalin for respiratory diseases: an update and future perspectives

in Respiratory Pharmacology

Siyu Song
Lu Ding
Guangwen Liu
Tian Chen
Meiru Zhao
Xueyan Li
Min Li
Hongyu Qi
Jinjin Chen
Ziyuan Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1129817

6,869 views
9 citations

Original Research

Published on 14 Mar 2023

Artesunate inhibits airway remodeling in asthma via the MAPK signaling pathway

in Respiratory Pharmacology

Mengyuan Zhang
Jiangtao Lin
Jingyuan Zhang
Ruiheng Zhao
Jingxuan Wan
Ying Nong

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1145188

3,258 views
8 citations

Original Research

Published on 14 Mar 2023

Arctiin-encapsulated DSPE-PEG bubble-like nanoparticles inhibit alveolar epithelial type 2 cell senescence to alleviate pulmonary fibrosis via the p38/p53/p21 pathway

in Respiratory Pharmacology

Dian Xiong
Fei Gao
Jingbo Shao
Yueyun Pan
Song Wang
Dong Wei
Shugao Ye
Yuan Chen
Rui Chen
Bingqing Yue

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1141800

4,340 views
9 citations

Original Research

Published on 09 Mar 2023

Sex-specific non-linear associations between body mass index and impaired pulmonary ventilation function in a community-based population: Longgang COPD study

in Respiratory Pharmacology

Hao Huang
Xueliang Huang
Jiaman Liao
Yushao Li
Yaoting Su
Yaxian Meng
Yiqiang Zhan

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1103573

2,374 views
1 citation

Perspective

Published on 09 Mar 2023

Current possibilities and future opportunities provided by three-dimensional lung ECM-derived hydrogels

in Respiratory Pharmacology

Mehmet Nizamoglu
Janette K. Burgess

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1154193

2,248 views
4 citations

Original Research

Published on 09 Mar 2023

Urolithin A (UA) attenuates ferroptosis in LPS-induced acute lung injury in mice by upregulating Keap1-Nrf2/HO-1 signaling pathway

in Respiratory Pharmacology

Lejing Lou
Min Wang
Jingjing He
Song Yang
Fanxi Meng
Shijia Wang
Xiao Jin
Jihao Cai
Chang Cai

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1067402

10,516 views
23 citations

Original Research

Published on 06 Mar 2023

A multiplex inhalation platform to model in situ like aerosol delivery in a breathing lung-on-chip

in Respiratory Pharmacology

Arunima Sengupta
Aurélien Dorn
Mohammad Jamshidi
Magali Schwob
Widad Hassan
Lea Lara De Maddalena
Andreas Hugi
Andreas O. Stucki
Patrick Dorn
Thomas M. Marti

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1114739

7,249 views
15 citations

Clinical Trial

Published on 27 Feb 2023

Jin-Zhen oral liquid for pediatric coronavirus disease (COVID-19): A randomly controlled, open-label, and non-inferiority trial at multiple clinical centers

in Respiratory Pharmacology

Qian Dong
Hongmei Qiao
Huiyi Jiang
Lixiao Liu
Yanling Ge
Fang-Jiao Zong
Yanan Li
Bingzi Dong
Sujuan Hu
Dongmei Meng

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1094089

2,349 views

Navigation group

Articles

Long-term effects of lumacaftor/ivacaftor on paranasal sinus abnormalities in children with cystic fibrosis detected with magnetic resonance imaging

Low-dose of caffeine alleviates high altitude pulmonary edema via regulating mitochondrial quality control process in AT1 cells

Sex chromosome complement and sex steroid signaling underlie sex differences in immunity to respiratory virus infection

Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor

Comparison of treatment persistence, adherence, and risk of exacerbation in patients with COPD treated with single-inhaler versus multiple-inhaler triple therapy: A prospective observational study in China

Functional enhancement strategies to potentiate the therapeutic properties of mesenchymal stromal cells for respiratory diseases

Better response to Tanreqing injection in frequent acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients—Real-world evidence from a nationwide registry (ACURE) study

The protective effects of baicalin for respiratory diseases: an update and future perspectives

Artesunate inhibits airway remodeling in asthma via the MAPK signaling pathway

Arctiin-encapsulated DSPE-PEG bubble-like nanoparticles inhibit alveolar epithelial type 2 cell senescence to alleviate pulmonary fibrosis via the p38/p53/p21 pathway

Sex-specific non-linear associations between body mass index and impaired pulmonary ventilation function in a community-based population: Longgang COPD study

Current possibilities and future opportunities provided by three-dimensional lung ECM-derived hydrogels

Urolithin A (UA) attenuates ferroptosis in LPS-induced acute lung injury in mice by upregulating Keap1-Nrf2/HO-1 signaling pathway

A multiplex inhalation platform to model in situ like aerosol delivery in a breathing lung-on-chip

Jin-Zhen oral liquid for pediatric coronavirus disease (COVID-19): A randomly controlled, open-label, and non-inferiority trial at multiple clinical centers